Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Rating Lowered by UBS Group

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) was downgraded by investment analysts at UBS Group from a "buy" rating to a "neutral" rating in a research note issued to investors on Thursday, Marketbeat reports. They currently have a $738.00 target price on the biopharmaceutical company's stock, down from their previous target price of $1,130.00. UBS Group's target price would suggest a potential upside of 6.46% from the company's previous close.

Other research analysts have also recently issued reports about the stock. Oppenheimer decreased their target price on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating for the company in a report on Wednesday, November 6th. Sanford C. Bernstein decreased their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a report on Tuesday, January 7th. Piper Sandler decreased their price objective on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating for the company in a report on Friday, November 1st. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating for the company in a report on Thursday, October 24th. Finally, Wolfe Research initiated coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They set an "outperform" rating and a $1,150.00 price objective for the company. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $1,015.38.

Regeneron Pharmaceuticals Stock Down 1.5 %

Regeneron Pharmaceuticals stock traded down $10.20 during trading hours on Thursday, hitting $693.23. The stock had a trading volume of 853,252 shares, compared to its average volume of 846,744. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $76.18 billion, a P/E ratio of 17.15, a price-to-earnings-growth ratio of 1.60 and a beta of 0.10. Regeneron Pharmaceuticals has a 12-month low of $666.25 and a 12-month high of $1,211.20. The stock's 50-day moving average price is $744.16 and its 200-day moving average price is $954.41.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently modified their holdings of REGN. International Assets Investment Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 86,013.3% in the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company's stock worth $926,078,000 after purchasing an additional 879,916 shares during the period. Worldquant Millennium Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $127,489,000. Icon Wealth Advisors LLC boosted its position in shares of Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company's stock worth $79,874,000 after purchasing an additional 75,569 shares during the period. State Street Corp boosted its position in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock worth $5,153,603,000 after acquiring an additional 61,277 shares during the last quarter. Finally, Epoch Investment Partners Inc. boosted its position in shares of Regeneron Pharmaceuticals by 57.7% during the second quarter. Epoch Investment Partners Inc. now owns 163,296 shares of the biopharmaceutical company's stock worth $171,629,000 after acquiring an additional 59,745 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.